ESRX Related Analyst EPS Change
-
Jefferies Upgrades Express Scripts (ESRX) to Buy; Uncertainties Gone & Repurchases Back
-
UBS Adjusts Numbers on Express Scripts (ESRX)
-
Jefferies Downgrades Express Scripts (ESRX) to Hold Post Q3 and Downbeat Outlook
-
Leerink Swann Downgrades AmerisourceBergen (ABC) to Market Perform; Headwinds Remove Positive N-T Catalysts
-
Goldman Sachs Resumes Coverage on SXC Health Solutions (SXCI) at Buy; Strong Growth Beyond Integration
-
Goldman Sachs Maintains a 'Neutral' on Rite-Aid (RAD); Same-Store Sales Reflect Impact of Generics
-
UBS Reiterates a 'Neutral' on Rite-Aid (RAD); A Few Longer-Term Tailwinds, But Staying Sidelined For Now
-
UBS Raises Numbers on CVS Caremark (CVS); Comments From Conference Call
-
Jefferies Reiterates a 'Buy' on Express Scripts (ESRX); Real Boost From MHS Acquisition
-
UBS Maintains a 'Buy' on Walgreen (WAG); Downside Risk Priced In, Creating Favorable Risk/Reward Balance
-
UBS Maintains a 'Buy' on CVS Caremark (CVS); Raising FY12/13 EPS Estimates
Back to ESRX Stock Lookup
